Bangalore, Oct 18: Reporting a 27 per cent growth in net profit, biotech major Biocon Limited today annmounced a revenue of Rs 553 crore and a net profit of Rs 107 crore for the first half of the current fiscal.
Consolidated Revenues grew by 19 per cent over the same period in the previous year. Research Services (Syngene) continued to deliver a robust dollar denominated growth of 60 per cent and an impressive 43 per cent based on Rupee realisation. Profit was restrained by rupee appreciation, the Company said in a release..
Biopharmaceuticals and branded formulations showed strong performance. Insulin was a significant contributor.
Technology and licensing revenues continued to contribute to H-1 financials.
The Company said its R and D expenditure increased to Rs 32 crore from Rs 19 crore in the previous year.